Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

Gynecologic Oncology

Volumn 119, Issue 3, 2010, Pages 484-490

  Han, Ernest S ^a,f   Burger, Robert A ^a,g   Darcy, Kathleen M ^b   Sill, Michael W ^b,c   Randall, Leslie M ^a   Chase, Dana ^a   Parmakhtiar, Basmina ^a   Monk, Bradley J ^a   Greer, Benjamin E ^d   Connelly, Patrick ^e   Degeest, Koen ^e   Fruehauf, John P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g FOX CHASE CANCER CENTER   (United States)

Author keywords

Angiogenesis; Bevacizumab; Biomarker; CD31; Ovarian cancer; VEGF

Indexed keywords

BEVACIZUMAB; CD31 ANTIGEN; PROTEIN P53; THROMBOSPONDIN 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL OVARIAN CANCER; FEMALE; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIMARY PERITONEAL CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROVESSELS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; THROMBOSPONDIN 1; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78149359739     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.08.016     Document Type: Article

References (40)

1. P.J. DiSaia, and W.T. Creasman Epithelial ovarian cancer P.J. DiSaia, W.T. Creasman, Clinical Gynecologic Oncology 7th ed. 2007 Mosby-Year Book St. Louis 313 367
2. M. Kowanetz, and N. Ferrara Vascular endothelial growth factor signaling pathways: therapeutic perspective Clin Cancer Res 12 2006 5018 5022
3. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study J Clin Oncol 25 2007 5165 5171
4. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186
5. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia J Clin Oncol 26 2008 76 82
6. A.M. Jubb, A.J. Oates, S. Holden, and H. Koeppen Predicting benefit from anti-angiogenic agents in malignancy Nat Rev Cancer 6 2006 626 635
7. R. Mehta, A. Kyshtoobayeva, T. Kurosaki, E.J. Small, H. Kim, and R. Stroup Independent association of angiogenesis index with outcome in prostate cancer Clin Cancer Res 7 2001 81 88
8. S. Sharma, M.C. Sharma, and C. Sarkar Morphology of angiogenesis in human cancers: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis Histopathology 46 2005 481 489
9. T.N. Wang, X. Qian, M.S. Granick, M.P. Solomon, V.L. Rothman, and D.H. Berger Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer J Surg Res 63 1996 39 43
10. G. Taraboletti, L. Morbidelli, S. Donnini, A. Parenti, H.J. Granger, and R. Giavazzi The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells FASEB J 14 2000 1674 1676
11. D.L. Weinstat-Saslow, V.S. Zabrenetzky, K. VanHoutte, W.A. Frazier, D.D. Roberts, and P.S. Steeg Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis Cancer Res 54 1994 6504 6511
12. V. Zabrenetzky, C.C. Harris, P.S. Steeg, and D.D. Roberts Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines Int J Cancer 1994 59191 59195
13. M.L. Iruela-Arispe, M. Lombardo, H.C. Krutzsch, J. Lawler, and D.D. Roberts Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats Circulation 100 1999 1423 1431
14. S. Kazerounian, K.O. Yee, and J. Lawler Thrombospondins in cancer Cell Mol Life Sci 65 2008 700 712
15. K.M. Darcy, W.E. Brady, J.W. McBroom, J.G. Bell, R.C. Young, and W.P. McGuire Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study Gynecol Oncol 111 2008 487 495
16. M. Hollander, and D.A. Wolfe Nonparametric Statistical Methods 1973 John Wiley & Sons New York
17. M.G. Kendall The treatment of ties in rank problems Biometrika 33 1945 239 251
18. S.B. Wedam, J.A. Low, S.X. Yang, C.K. Chow, P. Choyke, and D. Danforth Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol 24 2006 769 777
19. A.M. Jubb, H.I. Hurwitz, W. Bai, E.B. Holmgren, P. Tobin, and A.S. Guerrero Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer J Clin Oncol 24 2006 217 227
20. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
21. M. Pàez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, and F. Viñals Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
22. P.S. Steeg, R.L. Anderson, M. Bar-Eli, A.F. Chambers, S.A. Eccles, and K. Hunter Preclinical drug development must consider the impact on metastasis Clin Cancer Res 15 2009 4529 4530
23. S. Loges, M. Mazzone, P. Hohensinner, and P. Carmeliet Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited Cancer Cell 15 2009 167 170
24. H.C. Hollingsworth, E.C. Kohn, S.M. Steinberg, M.L. Rothenberg, and M.J. Merino Tumor angiogenesis in advanced stage ovarian carcinoma Am J Pathol 147 1995 9 19
25. A.A. Alvarez, H.R. Krigman, R.S. Whitaker, R.K. Dodge, and G.C. Rodriquez The prognostic significance of angiogenesis in epithelial ovarian carcinoma Clin Cancer Res 5 1999 587 591
26. M.J. Goodheart, M.A. Vasef, A.K. Sood, C.S. Davis, and R.E. Buller Ovarian cancer p53 mutation is associated with tumor microvessel density Gynecol Oncol 86 2002 85 90
27. A. Ferrero, P. Zola, S. Mazzola, L. Fuso, I. Sarotto, and N. Ravarino Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer Gynecol Oncol 95 2004 323 329
28. J.M. Rubatt, K.M. Darcy, A. Hutson, S.M. Bean, L.J. Havrilesky, and L.A. Grace Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study Gynecol Oncol 112 2009 469 474
29. A.A. Secord, K.M. Darcy, A. Hutson, P.S. Lee, L.J. Havrilesky, and L.A. Grace Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 105 2007 221 232
30. S.A. O'Toole, B.L. Sheppard, A. Laios, J.J. O'Leary, E.P. McGuinness, and T. D'Arcy Potential predictors of chemotherapy response in ovarian cancer: how do we define chemosensitivity? Gynecol Oncol 104 2007 345 351
31. T.J. Duncan, A. Al-Attar, P. Rolland, I.V. Scott, S. Deen, and D.T. Liu Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14 2008 3030 3035
32. A.A. Alvarez, J.R. Axelrod, R.S. Whitaker, P.D. Isner, R.C. Bentley, and R.K. Dodge Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients Gynecol Oncol 82 2001 273 278
33. S.W. Grant, A. Kyshtoobayeva, T. Kurosaki, J. Jakowatz, and J.P. Fruehauf Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma Cancer Detect Prev 22 1998 185 194
34. T. Soussi The p53 tumor suppressor gene: from molecular biology to clinical investigation Ann NY Acad Sci 910 2000 121 137
35. R.J. Steele, and D.P. Lane P53 in cancer: a paradigm for modern management of cancer Surgeon 3 2005 197 205
36. L. Havrilesky, K.M. Darcy, H. Hamdan, R.L. Priore, J. Leon, and J. Bell Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3814 3825
37. J. Adams, P.J. Carder, S. Downey, M.A. Forbes, K. MacLennan, and V. Allgar Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen Cancer Res 60 2000 2898 2905
38. R.E. Banks, M.A. Forbes, S.E. Kinsey, A. Stanley, E. Ingham, and C. Walters Release of angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology Br J Cancer 77 1998 956 964
39. F. Loupakis, A. Falcone, G. Masi, A. Fioravanti, R.S. Kerbel, and M. Del Tacca Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity J Clin Oncol 25 2007 1816 1818
40. R.A. Burger, M.F. Brady, M.A. Bookman, J.L. Walker, H.D. Homesley, and J. Fowler Phase III trial of bevacizumab (Bev) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study J Clin Oncol 28 2010 18s